Hua Medicine (Shanghai) Ltd. (HUMDF)
HUMDF Stock Price Chart
Explore Hua Medicine (Shanghai) Ltd. interactive price chart. Choose custom timeframes to analyze HUMDF price movements and trends.
HUMDF Company Profile
Discover essential business fundamentals and corporate details for Hua Medicine (Shanghai) Ltd. (HUMDF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
15 Mar 2021
Employees
168.00
Website
https://www.huamedicine.comCEO
Li Chen
Description
Hua Medicine (Shanghai) Ltd. operates as a clinical-stage drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin that is in Phase I clinical trial for treatment of T2D. The company also offers Dorzagliatin in combination with Pioglitazone for NASH; in combination with GLP-1 for Alzheimer diseases; and in combination with late stage T2D and Type 1 Diabetes. In addition, it is developing mGLUR5 for the treatment of Parkinson's disease levodopa-induced dyskinesia. The company was incorporated in 2011 and is based in Beijing, China.
HUMDF Financial Timeline
Browse a chronological timeline of Hua Medicine (Shanghai) Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 25 Mar 2026
Upcoming earnings on 25 Mar 2026
Earnings released on 28 Aug 2025
EPS came in at $0.16 , while revenue for the quarter reached $30.12M .
Earnings released on 27 Jun 2025
Earnings released on 27 Mar 2025
Earnings released on 29 Aug 2024
EPS came in at -$0.01 , while revenue for the quarter reached $7.06M .
Earnings released on 27 Jun 2024
EPS came in at -$0.01 , while revenue for the quarter reached $7.10M .
Earnings released on 28 Mar 2024
EPS came in at -$0.01 falling short of the estimated $0.07 by -111.37%, while revenue for the quarter reached $429.73K , missing expectations by -99.61%.
Earnings released on 31 Dec 2023
EPS came in at -$0.01 , while revenue for the quarter reached $443.27K .
Earnings released on 30 Jun 2023
EPS came in at -$0.01 , while revenue for the quarter reached $4.85M .
Earnings released on 31 Mar 2023
EPS came in at -$0.01 falling short of the estimated $0.05 by -114.01%, while revenue for the quarter reached $5.11M , missing expectations by -93.65%.
Earnings released on 31 Dec 2022
EPS came in at -$0.01 , while revenue for the quarter reached $1.29M .
Earnings released on 30 Sept 2022
EPS came in at -$0.01 falling short of the estimated $0.03 by -123.01%, while revenue for the quarter reached $1.23M , missing expectations by -98.33%.
Earnings released on 30 Jun 2022
EPS came in at -$0.01 .
Earnings released on 31 Mar 2022
EPS came in at -$0.01 surpassing the estimated -$0.03 by +72.62%.
Earnings released on 31 Dec 2021
EPS came in at -$0.01 , while revenue for the quarter reached -$37.76K .
Earnings released on 30 Sept 2021
EPS came in at -$0.01 surpassing the estimated -$0.03 by +53.23%, while revenue for the quarter reached -$37.26K .
Earnings released on 30 Jun 2021
EPS came in at -$0.01 , while revenue for the quarter reached $37.19K .
Earnings released on 31 Mar 2021
EPS came in at -$0.01 surpassing the estimated -$0.04 by +64.27%, while revenue for the quarter reached $36.63K .
Earnings released on 31 Dec 2020
EPS came in at -$0.02 , while revenue for the quarter reached $638.57K .
Earnings released on 30 Sept 2020
EPS came in at -$0.02 surpassing the estimated -$0.04 by +60.00%, while revenue for the quarter reached $613.36K .
HUMDF Stock Performance
Access detailed HUMDF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.